U.S. flag

An official website of the United States government, Department of Justice.

NCJRS Virtual Library

The Virtual Library houses over 235,000 criminal justice resources, including all known OJP works.
Click here to search the NCJRS Virtual Library

Project DAWN III

NCJ Number
235422
Date Published
1975
Length
411 pages
Annotation
This statistical report from the U.S. Department of Justice, Drug Enforcement Administration, presents information on the third phase of data collection concerning drug-abuse episodes for the period April, 1974 through April, 1975, as obtained from the Drug Abuse Warning Network.
Abstract
Highlights from this report include: for the period April, 1974, through April, 1975, there were 192,379 drug-abuse episodes reported at medical facilities involved in the Drug Abuse Warning Network (DAWN) Project that involved 266,880 drug mentions. Of the individuals involved in the 192,379 drug-abuse episodes, 76 percent were White and 21 percent were Black, with the majority concentrated in the 10-29 year age group. Of the 266,880 drug mentions, 10 substances accounted for 46 percent of the most frequently mentioned drugs: diazepam, alcohol-in-combination, aspirin, LSD, marijuana, chlordiazepoxide, d-Propoxyphene, flurazepam, heroin, and secobarbital. Additional data are provided on the demographics of drug use for each SMSA (standard metropolitan statistical area) and for each type of medical facility: emergency rooms, inpatient units, crisis center, and medical examiners offices. This report presents data on drug-abuse episodes and drug mentions collected through DAWN for the period April, 1974, through April, 1975, the third phase of the DAWN project. For this report, data were obtained from 1,265 hospital emergency rooms, hospital inpatient units, county medical examiners, student health centers, and crisis centers, located in 29 SMSAs (standard metropolitan statistical areas). DAWN is a large-scale, ongoing drug abuse collection system with several objectives: identifying substances associated with drug abuse episodes; monitoring drug abuse patterns and trends; assessing health hazards associated with drug abuse; and providing data for national, State, and local drug abuse policy and program planning. Tables and figures